Development of neuroleptic malignant syndrome during simultaneous amoxapine treatment and alprazolam discontinuation.
D000525:Alprazolam / Q000009:adverse effects*; D000657:Amoxapine / Q000009:adverse effects*; D003989:Dibenzoxazepines / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D013375:Substance Withdrawal Syndrome / Q000150:complications
D003989:Dibenzoxazepines; D000657:Amoxapine; D000525:Alprazolam